Mumbai, August 7, 2025 — Indian pharmaceutical giant Lupin is drawing up a multi-pronged strategy to navigate the looming threat of U.S. tariffs, while celebrating a robust 52% year-on-year surge in its Q1 net profit.
The company reported a profit after tax (PAT) of ₹1,221 crore for the quarter ended June 30, 2025, up from ₹805 crore in the same period last year. Revenues rose to ₹6,163 crore, reflecting a near 12% growth over ₹5,514 crore in Q1 FY25.
A large part of this growth came from the United States, which contributed 39% to Lupin’s Q1 revenues. India, Lupin’s second-largest market, contributed 34%.
U.S. Tariff Threat Sparks Strategic Recalibration
Addressing analysts post-results, CEO Vinita Gupta said the company is proactively preparing for the uncertain outcome of the ongoing Section 232 investigation in the U.S., which could potentially impose tariffs of up to 250% on imports — including pharmaceutical products.
“While tariffs in the 10–15% range are manageable, anything beyond that would significantly impact affordability for U.S. patients,” Gupta warned.
To mitigate this risk, Lupin is accelerating tech transfers to its U.S.-based manufacturing units and exploring intellectual property (IP) shifts for high-value drugs. The company is also evaluating price increases on certain products where market conditions permit flexibility.
“Lupinhttp://Lupin is deeply committed to ensuring the affordability of medicines, especially in the U.S.,” added Ramesh Swaminathan, Executive Director and Global CFO. “But high tariffs would harm patients and disrupt the generic medicine ecosystem.”
Momentum Builds for Blockbuster Drugs Like Semaglutide
Lupin is preparing to be among the first wave of companies manufacturing semaglutide — a blockbuster anti-diabetic and weight loss drug — as it goes off patent early next year. This strategic move could unlock a major growth channel in the coming quarters.
Managing Director Nilesh Gupta emphasized the company’s sharpened focus on compliance, innovation, and technology, saying: “These pillars position us to unlock sustainable growth in the years ahead.”
Solid Q1 Performance Across Markets
Lupin’s U.S. business clocked ₹2,404 crore in Q1 sales — up 24.3% over the same period last year. In India, sales reached ₹2,089 crore, marking a 7.8% rise year-on-year. The company also ramped up R&D investments to ₹484 crore this quarter, up from ₹350 crore in Q1 FY25, signaling its long-term innovation commitment.
Outlook: Resilience Amid Global Trade Tensions
As geopolitical and trade uncertainties loom large, Lupin’s leadership remains confident in its ability to adapt. With a focus on diversification, local manufacturing, and high-value therapies, the company is building resilienceo its global operations.
